AbbVie Inc. beat EPS estimates 95% of the time across 19 reported quarters (18 beats, 1 misses). Data sourced from SEC EDGAR.
| Quarter | EPS Estimate | EPS Actual | Surprise | Result |
|---|---|---|---|---|
| Q22026 FY2026 | $3.66 | — | — | Miss |
| Q12026 FY2026 | $2.62 | $2.65 | +1.1% | Beat |
| Q42025 FY2025 | $2.66 | $2.71 | +1.9% | Beat |
| Q42024 FY2024 | $2.98 | $2.16 | -27.5% | Miss |
| Q42023 FY2023 | $2.76 | $2.79 | +1.1% | Beat |
| Q3 FY2023 | $2.86 | $2.95 | +3.1% | Beat |
| Q2 FY2023 | $2.79 | $2.91 | +4.3% | Beat |
| Q1 FY2023 | $2.44 | $2.46 | +0.8% | Beat |
| Q42022 FY2022 | $3.54 | $3.60 | +1.7% | Beat |
| Q32022 FY2022 | $3.56 | $3.66 | +2.8% | Beat |
| Q22022 FY2022 | $3.31 | $3.37 | +1.8% | Beat |
| Q12022 FY2022 | $3.14 | $3.24 | +3.2% | Beat |
Back to ABBV overview · ABBV holders · ABBV KPIs
Data sourced from U.S. SEC EDGAR filings. Not personalized investment advice.